International Clinical Trial: Clinical Study on Feasibility, Efficacy and Safety of Short Term Induced Redifferentiation with Zurletrectinib to Promote Iodine Uptake in NTRK Fusion Positive Radioiodine Refractory Differentiated Thyroid Cancer (RAIR-DTC)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133671) titled 'Clinical Study on Feasibility, Efficacy and Safety of Short Term Induced Redifferentiation with Zurletrectinib to Promote Iodine Uptake in NTRK Fusion Positive Radioiodine Refractory Differentiated Thyroid Cancer (RAIR-DTC)' on Sept. 30.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Peking Union Medical College Hospital

Condition: NTRK-fusion-positive RAIR-DTC

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-09-30

Target Sample Size: Experimental group:14;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.h...